Cryoport, a cryogenic logistics company, said Wednesday that it will assist Sanaria in the design and implementation of the cryogenic cold chain for Sanaria’s investigational malaria vaccines.
This work is supported by grants to Sanaria from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and U.S. Department of Defense (DoD). Cryoport’s expertise in cryogenic logistics will be applied to distribution models for Sanaria PfSPZ Vaccine for travel clinics (NIAID, NIH grant) and the U.S. military (DoD grant).
This work will assist in the implementation of Phase 3 clinical trials of the vaccine and the development of cryogenic logistics distribution in support of the anticipated commercial launch of PfSPZ Vaccine, which is cryopreserved. Sanaria’s malaria vaccines have achieved more than 90% protection in multiple clinical trials to date. Current clinical studies aim to finalize the regimen for the traveler’s indication.